1.Expert consensus on rehabilitation strategies for traumatic spinal cord injury
Liehu CAO ; Feng NIU ; Wencai ZHANG ; Qiang YANG ; Shijie CHEN ; Guoqing YANG ; Boyu WANG ; Yanxi CHEN ; Guohui LIU ; Dongliang WANG ; Ximing LIU ; Xiaoling TONG ; Guodong LIU ; Hongjian LIU ; Tao LUO ; Zhongmin SHI ; Biaotong HUANG ; Wenming CHEN ; Qining WANG ; Shaojun SONG ; Lili YANG ; Tongsheng LIU ; Dawei HE ; Zhenghong YU ; Jianzheng ZHANG ; Zhiyong HOU ; Zengwu SHAO ; Dianying ZHANG ; Haodong LIN ; Baoqing YU ; Yunfeng CHEN ; Xiaodong ZHU ; Qinglin HANG ; Zhengrong GU ; Xiao CHEN ; Yan HU ; Liming XIONG ; Yunfei ZHANG ; Yong WANG ; Lei ZHANG ; Lei YANG ; Peijian TONG ; Jinpeng JIA ; Peng ZHANG ; Yong ZHANG ; Kuo SUN ; Tao SHEN ; Shiwu DONG ; Jianfei WANG ; Hongliang WANG ; Yong FENG ; Zhimin YING ; Chengdong HU ; Ming LI ; Xiaotao CHEN ; Weiguo YANG ; Xing WU ; Jiaqian ZHOU ; Haidong XU ; Bobin MI ; Yingze ZHANG ; Jiacan SU
Chinese Journal of Trauma 2020;36(5):385-392
TSCI have dyskinesia and sensory disturbance that can cause various life-threaten complications. The patients with traumatic spinal cord injury (TSCI), seriously affecting the quality of life of patients. Based on the epidemiology of TSCI and domestic and foreign literatures as well as expert investigations, this expert consensus reviews the definition, injury classification, rehabilitation assessment, rehabilitation strategies and rehabilitation measures of TSCI so as to provide early standardized rehabilitation treatment methods for TSCI.
2.Research status and advances in immunotherapy for chronic myeloid leukemia
Mengmeng WANG ; Jingyun MA ; Boyu XIONG ; Zhuowen DAI ; Yueyue PAN ; Qiong WANG
Chinese Journal of Blood Transfusion 2025;38(5):739-746
Chronic myeloid leukemia (CML) is a malignant hematologic disorder caused by abnormal proliferation of hematopoietic stem cells. In recent years, while the application of tyrosine kinase inhibitors (TKIs) has significantly improved the prognosis of CML patients through in-depth exploration of pathogenesis of CML and advancements in targeted therapies, some patients still face challenges including drug resistance, disease relapse, and failure to achieve treatment-free remission. Imunotherapy, as a complementary or alternative strategy, holds significant potential for overcoming these limitations, and has gradually emerged as a critical research focus in CML treatment. This review aims to summarize the current research status and latest advances in immunotherapy for CML.